Stock Events

Stock Events

Alnylam Pharmaceuticals 

$266.11
200
+$1.61+0.61% 20:00 Today
+$0.39+0.15%21:22After hours

Statistics

Day High
266.85
Day Low
258.02
52W High
495.55
52W Low
197.81
Volume
1,420,329
Avg. Volume
1,803,892
Mkt Cap
35.61B
P/E Ratio
75.25
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.89
0.02
0.93
1.84
Expected EPS
1.774695
Actual EPS
N/A

Financials

8.45%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
3.71BRevenue
313.75MNet Income

Analyst Ratings

360.56Average Price Target
The highest estimate is 455.00.
From 16 ratings within the last 6 months. This is not an investment recommendation.
Buy
81%
Hold
19%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALNY. It's not an investment recommendation.
NVIDIA
51
NVDA
Microsoft
47
MSFT
Apple
44
AAPL
Amazon
44
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals competes directly with Alnylam in the development of RNA-targeted therapies.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap11.99B
Arrowhead Pharmaceuticals is a direct competitor in RNA interference (RNAi) therapeutics, similar to Alnylam's core technology.
Moderna
MRNA
Mkt Cap55.09B
Moderna, Inc. competes in the broader RNA space with its mRNA technology, which can be seen as complementary or competitive to Alnylam's RNAi.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical competes with Alnylam in the rare disease space, particularly in treatments that could overlap with Alnylam's patient populations.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics, focusing on RNA-based therapies, particularly for rare diseases, competes for similar patient populations and therapeutic areas as Alnylam.
Novartis
NVS
Mkt Cap292.35B
Novartis AG has a broad interest in RNA-based therapies and has been involved in collaborations and competition in the RNA space, including areas Alnylam is targeting.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a diverse portfolio that includes investments in RNA therapies and rare diseases, making it a competitor on multiple fronts.

About

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Show more...
CEO
Yvonne L. Greenstreet
Employees
2500
Country
United States
ISIN
US02043Q1076
WKN
000A0CBCK

Listings

MI
IT
1ALNY.MI
STU
DE
DUL.STU
XETRA
DE
DUL.XETRA
MX
MX
ALNY.MX

0 Comments

Share your thoughts

FAQ

What is Alnylam Pharmaceuticals stock price today?▼
The current price of ALNY is $266.11 USD — it has increased by +0.61% in the past 24 hours. Watch Alnylam Pharmaceuticals stock price performance more closely on the chart.
What is Alnylam Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Alnylam Pharmaceuticals stocks are traded under the ticker ALNY.
Is Alnylam Pharmaceuticals stock price growing?▼
ALNY stock has risen by +12.24% compared to the previous week, the month change is a +21.51% rise, over the last year Alnylam Pharmaceuticals has showed a -41.33% decrease.
What is Alnylam Pharmaceuticals market cap?▼
Today Alnylam Pharmaceuticals has the market capitalization of 35.61B
When is the next Alnylam Pharmaceuticals earnings date?▼
Alnylam Pharmaceuticals is going to release the next earnings report on October 29, 2026.
What were Alnylam Pharmaceuticals earnings last quarter?▼
ALNY earnings for the last quarter are 1.21 USD per share, whereas the estimation was 1.63 USD resulting in a -25.78% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Alnylam Pharmaceuticals revenue for the last year?▼
Alnylam Pharmaceuticals revenue for the last year amounts to 3.71B USD.
What is Alnylam Pharmaceuticals net income for the last year?▼
ALNY net income for the last year is 313.75M USD.
How many employees does Alnylam Pharmaceuticals have?▼
As of September 04, 2026, the company has 2,500 employees.
In which sector is Alnylam Pharmaceuticals located?▼
Alnylam Pharmaceuticals operates in the Health & Wellness sector.
When did Alnylam Pharmaceuticals complete a stock split?▼
Alnylam Pharmaceuticals has not had any recent stock splits.
Where is Alnylam Pharmaceuticals headquartered?▼
Alnylam Pharmaceuticals is headquartered in CAMBRIDGE, United States.